CEORoadShow
Media & Internet · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Exchange Plz Fl 19, New York City, New...Phone Number
(949) 306-6476Website
www.ceoroadshow.comRevenue
$7.4 MillionIndustry
About CEORoadShow
Is CEORoadShow your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at CEORoadShow
Funding: Get notified immidiatlly once CEORoadShow has new funding data
CEORoadShow, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when CEORoadShow launches new products
Check out if CEORoadShow is spiking on competitors!
Check if CEORoadShow has recently received funding, and reach out quickly before it becomes old news!
Click to see if CEORoadShow had a recent Job posting/layoffs
Earning: See what the market has to say on CEORoadShow recently announced quarterly report
Recommended Actions
Find VP level buyers at CEORoadShow
Find more new buyers
Compare Similar Companies to CEORoadShow
Compare insights from companies similar to CEORoadShow, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
CEORoadShow
CEORoadShow Tech Stack
A closer look at the technologies used by CEORoadShow
CEORoadShow News & Media
Bebuzee, Inc. CEO & Founder Joe Onyero Interviewed on CEORoadshow
MIAMI, FLORIDA, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Bebuzee, Inc. (OTC Pink: ENGA) a social platform and streaming service focused on the development and deployment of America’s first SuperApp, today announces that CEO Joe Onyero has been featured on CEO Roadshow.Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma
ORLANDO, FL, May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced it is making progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer.Innovus Pharmaceuticals Continues Strong Revenue Growth & New Product Rollouts
CEOLIVE Exclusive Interview with Dr. Bassam Damaj, President & CEO of Innovus Pharmaceuticals (INNV)
Top Media & Internet Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CEORoadShow
CEORoadshow provides a platform that connects real investors directly with CEOs, financial influencers, and top-performing advisors, offering insights and content that go beyond traditional investment sources. Subscribers gain access to premium content, in-depth interviews, and innovative analytical tools designed to elevate their investing strateg... Read More